FACTOID # 18: Alaska spends more money per capita on elementary and secondary education than any other state.
 
 Home   Encyclopedia   Statistics   States A-Z   Flags   Maps   FAQ   About 
   
 
WHAT'S NEW
RELATED ARTICLES
People who viewed "ZymoGenetics" also viewed:
 

SEARCH ALL

FACTS & STATISTICS    Advanced view

Search encyclopedia, statistics and forums:

 

 

(* = Graphable)

 

 


Encyclopedia > ZymoGenetics

ZymoGenetics is a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of therapeutic proteins.


The company was founded in 1981 by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia. Soon after its founding, ZymoGenetics began working on recombinant proteins with Denmark's Novo Nordisk, and was acquired by that company in 1988. It was spun off as a public company in 2000, and its shares trade on the NASDAQ stock market under the ticker symbol ZGEN.


ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.


External links

  • http://www.zymogenetics.com/

  Results from FactBites:
 
ZymoGenetics - Wikipedia, the free encyclopedia (188 words)
ZymoGenetics is a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of therapeutic proteins.
The company was founded in 1981 by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.
ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.
ZymoGenetics News (598 words)
ZymoGenetics, Inc. and Serono today announced favorable results from a Phase 1b clinical trial with TACI-Ig in 73 patients with rheumatoid arthritis, recently presented at the 7th Annual European Congress of...
ZymoGenetics said today it has finished enrolling patients in a final-stage clinical trial of its Thrombin treatment for surgical bleeding.
ZymoGenetics, Inc. today announced it has completed patient enrollment for a Phase 3 pivotal clinical trial of recombinant human thrombin as an aid to controlling blood loss during surgery.
  More results at FactBites »

 
 

COMMENTARY     


Share your thoughts, questions and commentary here
Your name
Your comments

Want to know more?
Search encyclopedia, statistics and forums:

 


Press Releases |  Feeds | Contact
The Wikipedia article included on this page is licensed under the GFDL.
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms, 1022, m